Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eleven Biotherapeutics (EBIO) PT Raised to $8 at Leerink Partners
August 13, 2015 2:13 PM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on Eleven Biotherapeutics (NASDAQ: EBIO) from $6 up to $8.35 following Q2 results and upside to EBI-005 phase 3 readout.
Gerberry noted that EBIO's Q2 loss of about $7 million was slightly narrower than the firm's outlook for a loss of about $8 million, which... More
Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c
August 13, 2015 7:32 AM EDTEleven Biotherapeutics (NASDAQ: EBIO) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $114 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
... More